Johnson & Johnson Q2: Robust New Product Pipeline

JHVEPhoto I initiated a “Buy” rating for Johnson & Johnson (NYSE:JNJ) in January 2024, highlighting its balanced growth between MedTech and medicine business. The company released its Q2 FY24 results on July 17th, beating the market estimates for both the top line and bottom line. I am encouraged by the company’s strong product pipeline, and the recent acquisition of Shockwave Medical. I reiterate a “Buy” rating with a fair value of $190 per share. Robust Product Pipeline  Johnson & Johnson delivered 6. ...